Are you over 18 and want to see adult content?
More Annotations
A complete backup of notitle-weblog.com
Are you over 18 and want to see adult content?
A complete backup of oakpa.weebly.com
Are you over 18 and want to see adult content?
A complete backup of paradiseschools.org
Are you over 18 and want to see adult content?
A complete backup of shtepiaelibrit.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of southregionaltafe.wa.edu.au
Are you over 18 and want to see adult content?
A complete backup of volha.livejournal.com
Are you over 18 and want to see adult content?
A complete backup of anglersmail.co.uk
Are you over 18 and want to see adult content?
A complete backup of referralmagic.co
Are you over 18 and want to see adult content?
A complete backup of luialetto.wordpress.com
Are you over 18 and want to see adult content?
A complete backup of lespritsorcier.org
Are you over 18 and want to see adult content?
A complete backup of holabirdamericana.com
Are you over 18 and want to see adult content?
Text
therapies.
ABOUT US | AGIOS | THE OTHER SIDE OF POSSIBLE Agios’ mission is to create differentiated, small molecule medicines for people living with genetically defined diseases. Our scientific focus is on discovering and developing innovative therapies based on our core expertise in cellular metabolism. We’re a company that cares about our work, each other, and the people who are counting onus
PIPELINE | AGIOS | THE OTHER SIDE OF POSSIBLE Agios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline, Agios has a first-in-class investigational therapy in clinical development. AGIOS ANNOUNCES CLOSING OF ONCOLOGY BUSINESS SALE TO Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio. Agios Enters Into Agreement to Repurchase Approximately 10% of Its Outstanding Shares from Bristol-Myers Squibb for $344.5 Million. CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular AGIOS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for TIBSOVO ® (ivosidenib tablets) as a potential treatment for AGIOS ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients AGILE: PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO 2 Mutations in IDH1 occur in ~6– 10% of AML cases 1–4 Ivosidenib (AG-120) is a first -in-class, oral, potent, targeted, small -molecule inhibitor of the mIDH1 enzyme that is being tested in multiple clinical studies Ivosidenib is approved in the US for the treatment of AML with a susceptible IDH1 mutation as detected by an FDA-approved test in adults with newly diagnosed AML who are ≥ 75 ANNUAL REPORTS & PROXY Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Stock is. Shareholder Tools.QUARTERLY RESULTS
Q1 2019 Earnings. Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call. First Quarter 2019 Financial Results Presentation. 607.2 KB. Agios Reports Business Highlights and First Quarter 2019 Financial Results. 10-Q Quarterly Report. 514.2 KB.JACQUALYN FOUSE
Jacqualyn Fouse Ph.D. Dr. Fouse has served as a member of our board of directors since December 2017. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors through June 2017. Dr. AGIOS | THE OTHER SIDE OF POSSIBLERESEARCHNEWS & EVENTSCONTACT USCANCER METABOLISMPUBLICATIONSEVENTS & WEBCASTS Spirit of Agios. Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, values and competencies. We have built on our core differentiators to make a positive difference for patients through truly differentiatedtherapies.
ABOUT US | AGIOS | THE OTHER SIDE OF POSSIBLE Agios’ mission is to create differentiated, small molecule medicines for people living with genetically defined diseases. Our scientific focus is on discovering and developing innovative therapies based on our core expertise in cellular metabolism. We’re a company that cares about our work, each other, and the people who are counting onus
PIPELINE | AGIOS | THE OTHER SIDE OF POSSIBLE Agios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline, Agios has a first-in-class investigational therapy in clinical development. AGIOS ANNOUNCES CLOSING OF ONCOLOGY BUSINESS SALE TO Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio. Agios Enters Into Agreement to Repurchase Approximately 10% of Its Outstanding Shares from Bristol-Myers Squibb for $344.5 Million. CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular AGIOS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for TIBSOVO ® (ivosidenib tablets) as a potential treatment for AGIOS ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients AGILE: PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO 2 Mutations in IDH1 occur in ~6– 10% of AML cases 1–4 Ivosidenib (AG-120) is a first -in-class, oral, potent, targeted, small -molecule inhibitor of the mIDH1 enzyme that is being tested in multiple clinical studies Ivosidenib is approved in the US for the treatment of AML with a susceptible IDH1 mutation as detected by an FDA-approved test in adults with newly diagnosed AML who are ≥ 75 ANNUAL REPORTS & PROXY Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Stock is. Shareholder Tools.QUARTERLY RESULTS
Q1 2019 Earnings. Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call. First Quarter 2019 Financial Results Presentation. 607.2 KB. Agios Reports Business Highlights and First Quarter 2019 Financial Results. 10-Q Quarterly Report. 514.2 KB.JACQUALYN FOUSE
Jacqualyn Fouse Ph.D. Dr. Fouse has served as a member of our board of directors since December 2017. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors through June 2017. Dr. MEDICAL PROFESSIONALS Monday – Friday 7:00am – 6:00pm CT with urgent after hours. Report an Adverse Event or Product Complaint anytime. medinfo@agios.com. Phone: 833-228-8474. Fax: 901-432-3977. To submit a grant request for independent medical education, click here. To submit a grant request for independent, investigator-initiated research, click here.INSIDE AGIOS
Inside Agios. At Agios, we are doing incredibly important and difficult work. We are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with genetically defined diseases who are counting on us to be successful. It takes people with a diversity of thought, skills, passions and backgroundsto get us
LEADERSHIP | AGIOS | THE OTHER SIDE OF POSSIBLE Jacqualyn Fouse, Ph.D. Agios Pharmaceuticals. Dr. Fouse has served as a member of our board of directors since December 2017 and became chief executive officer of Agios in February 2019. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors AGIOS ANNOUNCES CLOSING OF ONCOLOGY BUSINESS SALE TO Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio. Agios Enters Into Agreement to Repurchase Approximately 10% of Its Outstanding Shares from Bristol-Myers Squibb for $344.5 Million. CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular 2021 AGIOS PHARMACEUTICALS ENVIRONMENTAL, SOCIAL … ESG Report 2021 ABOUT US Agios is a biopharmaceutical company focused on providing important medicines for some of the world’s most challenging diseases. EVENTS & PRESENTATIONS Q4 2020 Agios Pharmaceuticals Inc Earnings Conference Call. Feb 25, 2021 at 8:00 AM EST. Supporting Materials. Fourth Quarter 2020 Financial Results Presentation. 3.2 MB.INVESTOR OVERVIEW
The Investor Relations website contains information about Agios Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. AGIOS LAUNCHES ANEMIA ID, A NO-COST GENETIC TESTING CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the launch of Anemia ID, a program providing no-cost genetic testing for patients with suspected hereditary anemias. The next-generation sequencing panel consists of more than 50 genes and CORPORATE GOVERNANCE Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Stock is. Shareholder Tools. AGIOS AND CSTONE PHARMACEUTICALS ANNOUNCE EXCLUSIVE - Agios to Receive $12 Million Upfront Payment and is Eligible to Receive Development, Regulatory, and Sales-Based Milestones and Tiered Royalties - - Collaboration Provides Opportunity for Patients with IDH1m Cancers in Greater China to Benefit from Ivosidenib -. CAMBRIDGE, Mass. and SUZHOU, China, June 26, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a AGIOS | THE OTHER SIDE OF POSSIBLERESEARCHNEWS & EVENTSCONTACT USCANCER METABOLISMPUBLICATIONSEVENTS & WEBCASTS Spirit of Agios. Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, values and competencies. We have built on our core differentiators to make a positive difference for patients through truly differentiatedtherapies.
ABOUT US | AGIOS | THE OTHER SIDE OF POSSIBLE Agios’ mission is to create differentiated, small molecule medicines for people living with genetically defined diseases. Our scientific focus is on discovering and developing innovative therapies based on our core expertise in cellular metabolism. We’re a company that cares about our work, each other, and the people who are counting onus
PIPELINE | AGIOS | THE OTHER SIDE OF POSSIBLE Agios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline, Agios has a first-in-class investigational therapy in clinical development. AGIOS ANNOUNCES CLOSING OF ONCOLOGY BUSINESS SALE TO Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio. Agios Enters Into Agreement to Repurchase Approximately 10% of Its Outstanding Shares from Bristol-Myers Squibb for $344.5 Million. CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular AGIOS ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients AGIOS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for TIBSOVO ® (ivosidenib tablets) as a potential treatment for AGIOS SPONSORS PROGRAM PROMOTING HEALTH LITERACY FOR CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced it will sponsor Citizen Scientist: Unpacking the Science of Sickle Cell Disease, an initiative developed by the Sickle Cell Community Consortium (SCCC) to promote health literacy for ANNUAL REPORTS & PROXY Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Stock is. Shareholder Tools.QUARTERLY RESULTS
Q1 2019 Earnings. Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call. First Quarter 2019 Financial Results Presentation. 607.2 KB. Agios Reports Business Highlights and First Quarter 2019 Financial Results. 10-Q Quarterly Report. 514.2 KB.JACQUALYN FOUSE
Jacqualyn Fouse Ph.D. Dr. Fouse has served as a member of our board of directors since December 2017. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors through June 2017. Dr. AGIOS | THE OTHER SIDE OF POSSIBLERESEARCHNEWS & EVENTSCONTACT USCANCER METABOLISMPUBLICATIONSEVENTS & WEBCASTS Spirit of Agios. Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, values and competencies. We have built on our core differentiators to make a positive difference for patients through truly differentiatedtherapies.
ABOUT US | AGIOS | THE OTHER SIDE OF POSSIBLE Agios’ mission is to create differentiated, small molecule medicines for people living with genetically defined diseases. Our scientific focus is on discovering and developing innovative therapies based on our core expertise in cellular metabolism. We’re a company that cares about our work, each other, and the people who are counting onus
PIPELINE | AGIOS | THE OTHER SIDE OF POSSIBLE Agios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline, Agios has a first-in-class investigational therapy in clinical development. AGIOS ANNOUNCES CLOSING OF ONCOLOGY BUSINESS SALE TO Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio. Agios Enters Into Agreement to Repurchase Approximately 10% of Its Outstanding Shares from Bristol-Myers Squibb for $344.5 Million. CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular AGIOS ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients AGIOS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for TIBSOVO ® (ivosidenib tablets) as a potential treatment for AGIOS SPONSORS PROGRAM PROMOTING HEALTH LITERACY FOR CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced it will sponsor Citizen Scientist: Unpacking the Science of Sickle Cell Disease, an initiative developed by the Sickle Cell Community Consortium (SCCC) to promote health literacy for ANNUAL REPORTS & PROXY Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Stock is. Shareholder Tools.QUARTERLY RESULTS
Q1 2019 Earnings. Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call. First Quarter 2019 Financial Results Presentation. 607.2 KB. Agios Reports Business Highlights and First Quarter 2019 Financial Results. 10-Q Quarterly Report. 514.2 KB.JACQUALYN FOUSE
Jacqualyn Fouse Ph.D. Dr. Fouse has served as a member of our board of directors since December 2017. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors through June 2017. Dr. ABOUT US | AGIOS | THE OTHER SIDE OF POSSIBLE Agios’ mission is to create differentiated, small molecule medicines for people living with genetically defined diseases. Our scientific focus is on discovering and developing innovative therapies based on our core expertise in cellular metabolism. We’re a company that cares about our work, each other, and the people who are counting onus
PATIENT RESOURCES
Patient Resources. If you or your loved one is living with a genetically defined disease, you may wish to visit the following resources for more information about treatment, research, clinicaltrials
2021 AGIOS PHARMACEUTICALS ENVIRONMENTAL, SOCIAL … 2021 AGIOS PHARMACEUTICALS ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Font Used: Variable Regular Color Blue: Hex: #038087 CMYK: 93, 23, 4,0
INVESTOR OVERVIEW
The Investor Relations website contains information about Agios Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. AGIOS PRESENTS FINAL DATA FROM PHASE 3 CLARIDHY STUDY OF – Supplemental New Drug Application Planned for Submission in Q1 2021 – CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PHASE III INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation Ingo K Mellinghoff1, Martin J van den Bent2, Jennifer L Clarke3, Elizabeth A Maher4, Katherine B Peters5, Mehdi Touat6, John F de Groot7, Macarena I De La Fuente8, Isabel Arrillaga AGIOS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG – TIBSOVO ® is the First and Only Therapy Approved for Newly Diagnosed AML Patients with an IDH1 Mutation who are Ineligible for Intensive Chemotherapy – – sNDA Approval Based on 28 Newly Diagnosed Patients from Phase 1 Study of TIBSOVO ® in Advanced Hematologic Malignancies with an IDH1 Mutation 1 – – Single Agent TIBSOVO ® Demonstrated CR Rate of 28.6% and CR+CRh AGIOS ANNOUNCES THE RANDOMIZED PHASE 3 CLARIDHY TRIAL OF WARNINGS AND PRECAUTIONS. Differentiation Syndrome: See Boxed WARNING. In the clinical trial, 25% (7/28) of patients with newly diagnosed AML and 19% (34/179) of patients with relapsed or refractory AML treated with TIBSOVO ® experienced differentiation syndrome. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life THE OTHER SIDE OF POSSIBLE united states securities and exchange commission washington, dc 20549 form 10-k (mark one) annual report pursuant to section 13 or 15(d) of the securities exchange act of 1934 CLARIDHY: A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND 1 ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib vs placebo in patients with advanced cholangiocarcinoma with an isocitrate dehydrogenase 1 (IDH1) mutation AGIOS | THE OTHER SIDE OF POSSIBLERESEARCHNEWS & EVENTSCONTACT USCANCER METABOLISMPUBLICATIONSEVENTS & WEBCASTS Spirit of Agios. Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, values and competencies. We have built on our core differentiators to make a positive difference for patients through truly differentiatedtherapies.
ABOUT US | AGIOS | THE OTHER SIDE OF POSSIBLE Agios’ mission is to create differentiated, small molecule medicines for people living with genetically defined diseases. Our scientific focus is on discovering and developing innovative therapies based on our core expertise in cellular metabolism. We’re a company that cares about our work, each other, and the people who are counting onus
PIPELINE | AGIOS | THE OTHER SIDE OF POSSIBLE Agios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline, Agios has a first-in-class investigational therapy in clinical development.PATIENT RESOURCES
Patient Resources. If you or your loved one is living with a genetically defined disease, you may wish to visit the following resources for more information about treatment, research, clinicaltrials
AGIOS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for TIBSOVO ® (ivosidenib tablets) as a potential treatment for AGIOS ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients AGIOS SPONSORS PROGRAM PROMOTING HEALTH LITERACY FOR CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced it will sponsor Citizen Scientist: Unpacking the Science of Sickle Cell Disease, an initiative developed by the Sickle Cell Community Consortium (SCCC) to promote health literacy forQUARTERLY RESULTS
Q1 2019 Earnings. Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call. First Quarter 2019 Financial Results Presentation. 607.2 KB. Agios Reports Business Highlights and First Quarter 2019 Financial Results. 10-Q Quarterly Report. 514.2 KB. ANNUAL REPORTS & PROXY Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Stock is. Shareholder Tools.JACQUALYN FOUSE
Jacqualyn Fouse Ph.D. Dr. Fouse has served as a member of our board of directors since December 2017. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors through June 2017. Dr. AGIOS | THE OTHER SIDE OF POSSIBLERESEARCHNEWS & EVENTSCONTACT USCANCER METABOLISMPUBLICATIONSEVENTS & WEBCASTS Spirit of Agios. Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, values and competencies. We have built on our core differentiators to make a positive difference for patients through truly differentiatedtherapies.
ABOUT US | AGIOS | THE OTHER SIDE OF POSSIBLE Agios’ mission is to create differentiated, small molecule medicines for people living with genetically defined diseases. Our scientific focus is on discovering and developing innovative therapies based on our core expertise in cellular metabolism. We’re a company that cares about our work, each other, and the people who are counting onus
PIPELINE | AGIOS | THE OTHER SIDE OF POSSIBLE Agios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline, Agios has a first-in-class investigational therapy in clinical development.PATIENT RESOURCES
Patient Resources. If you or your loved one is living with a genetically defined disease, you may wish to visit the following resources for more information about treatment, research, clinicaltrials
AGIOS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for TIBSOVO ® (ivosidenib tablets) as a potential treatment for AGIOS ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients AGIOS SPONSORS PROGRAM PROMOTING HEALTH LITERACY FOR CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced it will sponsor Citizen Scientist: Unpacking the Science of Sickle Cell Disease, an initiative developed by the Sickle Cell Community Consortium (SCCC) to promote health literacy forQUARTERLY RESULTS
Q1 2019 Earnings. Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call. First Quarter 2019 Financial Results Presentation. 607.2 KB. Agios Reports Business Highlights and First Quarter 2019 Financial Results. 10-Q Quarterly Report. 514.2 KB. ANNUAL REPORTS & PROXY Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Stock is. Shareholder Tools.JACQUALYN FOUSE
Jacqualyn Fouse Ph.D. Dr. Fouse has served as a member of our board of directors since December 2017. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors through June 2017. Dr. ABOUT US | AGIOS | THE OTHER SIDE OF POSSIBLE Agios’ mission is to create differentiated, small molecule medicines for people living with genetically defined diseases. Our scientific focus is on discovering and developing innovative therapies based on our core expertise in cellular metabolism. We’re a company that cares about our work, each other, and the people who are counting onus
EHA 2021 | AGIOS | THE OTHER SIDE OF POSSIBLE Re-Imagining The Other Side of Possible A singular focus on genetically defined diseases.PATIENT RESOURCES
Patient Resources. If you or your loved one is living with a genetically defined disease, you may wish to visit the following resources for more information about treatment, research, clinicaltrials
EHA 2021 MEDICAL BOOTH The information provided on this site is intended for use by healthcare professionals practicing in the US and is intended to help healthcare professionals practicing in the US and Agios authorized persons find scientifically balanced, evidence-based information about Agios drugs, submit questions, ask for field medical follow-up, and explore links to professional and patient support resources. EHA 2021 PK RESOURCES PK Deficiency Through the Decade. Understand more about PK deficiency and read summaries of key research papers published over the past decade. The list of publications and information you gather can also be used to build more proactive discussions with your doctor.EHA 2021 DATA ROOM
Oral Presentations. Title: ACTIVATE: A Phase 3, randomized, multicenter, double-blind, placebo-controlled study of mitapivat in adults with pyruvate kinase deficiency who are not regularly transfused Live Q&A Session Date and Time: Tuesday, June 15, 2021 at 7:45 p.m. CEST / 1:45 p.m. ET Oral Abstract Session: Changing the scene in congenital anemiasINVESTOR OVERVIEW
Q1 2021 Agios Pharmaceuticals Inc Earnings Conference Call. Supporting Materials: First Quarter 2021 Financial Results Presentation. 1.2 MB. full article. Mar 17, 2021 at 9:20 AM EDT. AGIOS ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients 2021 AGIOS PHARMACEUTICALS ENVIRONMENTAL, SOCIAL … 2021 AGIOS PHARMACEUTICALS ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Font Used: Variable Regular Color Blue: Hex: #038087 CMYK: 93, 23, 4,0
AGIOS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG – TIBSOVO ® is the First and Only Therapy Approved for Newly Diagnosed AML Patients with an IDH1 Mutation who are Ineligible for Intensive Chemotherapy – – sNDA Approval Based on 28 Newly Diagnosed Patients from Phase 1 Study of TIBSOVO ® in Advanced Hematologic Malignancies with an IDH1 Mutation 1 – – Single Agent TIBSOVO ® Demonstrated CR Rate of 28.6% and CR+CRh AGIOS | THE OTHER SIDE OF POSSIBLERESEARCHNEWS & EVENTSCONTACT USCANCER METABOLISMPUBLICATIONSEVENTS & WEBCASTS Spirit of Agios. Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, values and competencies. We have built on our core differentiators to make a positive difference for patients through truly differentiatedtherapies.
PIPELINE | AGIOS | THE OTHER SIDE OF POSSIBLE Agios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline, Agios has a first-in-class investigational therapy in clinical development. LEADERSHIP | AGIOS | THE OTHER SIDE OF POSSIBLE Jacqualyn Fouse, Ph.D. Agios Pharmaceuticals. Dr. Fouse has served as a member of our board of directors since December 2017 and became chief executive officer of Agios in February 2019. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors AGIOS ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients ANNUAL REPORTS & PROXY Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Stock is. Shareholder Tools. AGIOS SPONSORS PROGRAM PROMOTING HEALTH LITERACY FOR CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced it will sponsor Citizen Scientist: Unpacking the Science of Sickle Cell Disease, an initiative developed by the Sickle Cell Community Consortium (SCCC) to promote health literacy for AGILE: PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO 2 Mutations in IDH1 occur in ~6– 10% of AML cases 1–4 Ivosidenib (AG-120) is a first -in-class, oral, potent, targeted, small -molecule inhibitor of the mIDH1 enzyme that is being tested in multiple clinical studies Ivosidenib is approved in the US for the treatment of AML with a susceptible IDH1 mutation as detected by an FDA-approved test in adults with newly diagnosed AML who are ≥ 75QUARTERLY RESULTS
Q1 2019 Earnings. Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call. First Quarter 2019 Financial Results Presentation. 607.2 KB. Agios Reports Business Highlights and First Quarter 2019 Financial Results. 10-Q Quarterly Report. 514.2 KB. 0001439222-20-000014 Feb 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings. Company. Agios Pharmaceuticals, Inc. AGIOS AND CSTONE PHARMACEUTICALS ANNOUNCE EXCLUSIVE - Agios to Receive $12 Million Upfront Payment and is Eligible to Receive Development, Regulatory, and Sales-Based Milestones and Tiered Royalties - - Collaboration Provides Opportunity for Patients with IDH1m Cancers in Greater China to Benefit from Ivosidenib -. CAMBRIDGE, Mass. and SUZHOU, China, June 26, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a AGIOS | THE OTHER SIDE OF POSSIBLERESEARCHNEWS & EVENTSCONTACT USCANCER METABOLISMPUBLICATIONSEVENTS & WEBCASTS Spirit of Agios. Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, values and competencies. We have built on our core differentiators to make a positive difference for patients through truly differentiatedtherapies.
PIPELINE | AGIOS | THE OTHER SIDE OF POSSIBLE Agios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline, Agios has a first-in-class investigational therapy in clinical development. LEADERSHIP | AGIOS | THE OTHER SIDE OF POSSIBLE Jacqualyn Fouse, Ph.D. Agios Pharmaceuticals. Dr. Fouse has served as a member of our board of directors since December 2017 and became chief executive officer of Agios in February 2019. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors AGIOS ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients ANNUAL REPORTS & PROXY Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Stock is. Shareholder Tools. AGIOS SPONSORS PROGRAM PROMOTING HEALTH LITERACY FOR CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced it will sponsor Citizen Scientist: Unpacking the Science of Sickle Cell Disease, an initiative developed by the Sickle Cell Community Consortium (SCCC) to promote health literacy for AGILE: PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO 2 Mutations in IDH1 occur in ~6– 10% of AML cases 1–4 Ivosidenib (AG-120) is a first -in-class, oral, potent, targeted, small -molecule inhibitor of the mIDH1 enzyme that is being tested in multiple clinical studies Ivosidenib is approved in the US for the treatment of AML with a susceptible IDH1 mutation as detected by an FDA-approved test in adults with newly diagnosed AML who are ≥ 75QUARTERLY RESULTS
Q1 2019 Earnings. Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call. First Quarter 2019 Financial Results Presentation. 607.2 KB. Agios Reports Business Highlights and First Quarter 2019 Financial Results. 10-Q Quarterly Report. 514.2 KB. 0001439222-20-000014 Feb 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings. Company. Agios Pharmaceuticals, Inc. AGIOS AND CSTONE PHARMACEUTICALS ANNOUNCE EXCLUSIVE - Agios to Receive $12 Million Upfront Payment and is Eligible to Receive Development, Regulatory, and Sales-Based Milestones and Tiered Royalties - - Collaboration Provides Opportunity for Patients with IDH1m Cancers in Greater China to Benefit from Ivosidenib -. CAMBRIDGE, Mass. and SUZHOU, China, June 26, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a EHA 2021 | AGIOS | THE OTHER SIDE OF POSSIBLE Re-Imagining The Other Side of Possible A singular focus on genetically defined diseases. EHA 2021 PK RESOURCES PK Deficiency Through the Decade. Understand more about PK deficiency and read summaries of key research papers published over the past decade. The list of publications and information you gather can also be used to build more proactive discussions with your doctor. EHA 2021 MEDICAL BOOTH The information provided on this site is intended for use by healthcare professionals practicing in the US and is intended to help healthcare professionals practicing in the US and Agios authorized persons find scientifically balanced, evidence-based information about Agios drugs, submit questions, ask for field medical follow-up, and explore links to professional and patient support resources.PATIENT RESOURCES
Patient Resources. If you or your loved one is living with a genetically defined disease, you may wish to visit the following resources for more information about treatment, research, clinicaltrials
EHA 2021 DATA ROOM
Oral Presentations. Title: ACTIVATE: A Phase 3, randomized, multicenter, double-blind, placebo-controlled study of mitapivat in adults with pyruvate kinase deficiency who are not regularly transfused Live Q&A Session Date and Time: Tuesday, June 15, 2021 at 7:45 p.m. CEST / 1:45 p.m. ET Oral Abstract Session: Changing the scene in congenital anemiasTERMS OF USE
Terms and Conditions Governing the Use of the Agios Website Introduction. Welcome to the Agios website (“website”). Agios created and maintains this website to provide information to and communicate better with physicians, patients, investors and others who may be interested in learning more about Agios and the products andservices it offers.
AGIOS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for TIBSOVO ® (ivosidenib tablets) as a potential treatment for AGIOS PRESENTS FINAL DATA FROM PHASE 3 CLARIDHY STUDY OF – Supplemental New Drug Application Planned for Submission in Q1 2021 – CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy 0001439222-20-000014 Feb 19, 2020. Document Date. Dec 31, 2019. Form Description. Annual report which provides a comprehensive overview of the company for the past year. Filing Group. Annual Filings. Company. Agios Pharmaceuticals, Inc. 0001439222-20-000059 Form. 10-Q. Filing Date. Jul 30, 2020. Document Date. Jun 30, 2020. Form Description. Quarterly report which provides a continuing view of a company's financial position. Filing Group. AGIOS | THE OTHER SIDE OF POSSIBLERESEARCHNEWS & EVENTSCONTACT USCANCER METABOLISMPUBLICATIONSEVENTS & WEBCASTS Spirit of Agios. Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, values and competencies. We have built on our core differentiators to make a positive difference for patients through truly differentiatedtherapies.
PATIENT RESOURCES
Patient Resources. If you or your loved one is living with a genetically defined disease, you may wish to visit the following resources for more information about treatment, research, clinicaltrials
LEADERSHIP | AGIOS | THE OTHER SIDE OF POSSIBLE Jacqualyn Fouse, Ph.D. Agios Pharmaceuticals. Dr. Fouse has served as a member of our board of directors since December 2017 and became chief executive officer of Agios in February 2019. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directorsINVESTOR OVERVIEW
Q1 2021 Agios Pharmaceuticals Inc Earnings Conference Call. Supporting Materials: First Quarter 2021 Financial Results Presentation. 1.2 MB. full article. Mar 17, 2021 at 9:20 AM EDT.TERMS OF USE
Terms and Conditions Governing the Use of the Agios Website Introduction. Welcome to the Agios website (“website”). Agios created and maintains this website to provide information to and communicate better with physicians, patients, investors and others who may be interested in learning more about Agios and the products andservices it offers.
EVENTS & PRESENTATIONS Q4 2020 Agios Pharmaceuticals Inc Earnings Conference Call. Feb 25, 2021 at 8:00 AM EST. Supporting Materials. Fourth Quarter 2020 Financial Results Presentation. 3.2 MB. ANNUAL REPORTS & PROXY Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Stock is. Shareholder Tools. AGIOS SPONSORS PROGRAM PROMOTING HEALTH LITERACY FOR CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced it will sponsor Citizen Scientist: Unpacking the Science of Sickle Cell Disease, an initiative developed by the Sickle Cell Community Consortium (SCCC) to promote health literacy forQUARTERLY RESULTS
Q1 2019 Earnings. Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call. First Quarter 2019 Financial Results Presentation. 607.2 KB. Agios Reports Business Highlights and First Quarter 2019 Financial Results. 10-Q Quarterly Report. 514.2 KB. CORPORATE GOVERNANCE Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Stock is. Shareholder Tools. AGIOS | THE OTHER SIDE OF POSSIBLERESEARCHNEWS & EVENTSCONTACT USCANCER METABOLISMPUBLICATIONSEVENTS & WEBCASTS Spirit of Agios. Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, values and competencies. We have built on our core differentiators to make a positive difference for patients through truly differentiatedtherapies.
PATIENT RESOURCES
Patient Resources. If you or your loved one is living with a genetically defined disease, you may wish to visit the following resources for more information about treatment, research, clinicaltrials
LEADERSHIP | AGIOS | THE OTHER SIDE OF POSSIBLE Jacqualyn Fouse, Ph.D. Agios Pharmaceuticals. Dr. Fouse has served as a member of our board of directors since December 2017 and became chief executive officer of Agios in February 2019. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directorsINVESTOR OVERVIEW
Q1 2021 Agios Pharmaceuticals Inc Earnings Conference Call. Supporting Materials: First Quarter 2021 Financial Results Presentation. 1.2 MB. full article. Mar 17, 2021 at 9:20 AM EDT.TERMS OF USE
Terms and Conditions Governing the Use of the Agios Website Introduction. Welcome to the Agios website (“website”). Agios created and maintains this website to provide information to and communicate better with physicians, patients, investors and others who may be interested in learning more about Agios and the products andservices it offers.
EVENTS & PRESENTATIONS Q4 2020 Agios Pharmaceuticals Inc Earnings Conference Call. Feb 25, 2021 at 8:00 AM EST. Supporting Materials. Fourth Quarter 2020 Financial Results Presentation. 3.2 MB. ANNUAL REPORTS & PROXY Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Stock is. Shareholder Tools. AGIOS SPONSORS PROGRAM PROMOTING HEALTH LITERACY FOR CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced it will sponsor Citizen Scientist: Unpacking the Science of Sickle Cell Disease, an initiative developed by the Sickle Cell Community Consortium (SCCC) to promote health literacy forQUARTERLY RESULTS
Q1 2019 Earnings. Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call. First Quarter 2019 Financial Results Presentation. 607.2 KB. Agios Reports Business Highlights and First Quarter 2019 Financial Results. 10-Q Quarterly Report. 514.2 KB. CORPORATE GOVERNANCE Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Stock is. Shareholder Tools. MEDICAL PROFESSIONALS Monday – Friday 7:00am – 6:00pm CT with urgent after hours. Report an Adverse Event or Product Complaint anytime. medinfo@agios.com. Phone: 833-228-8474. Fax: 901-432-3977. To submit a grant request for independent medical education, click here. To submit a grant request for independent, investigator-initiated research, click here. CONTACT US | AGIOS | THE OTHER SIDE OF POSSIBLE MEDICAL INFORMATION Medical Information Inquiries. Agios Medical Information Call Center; Monday – Friday 7:00am – 6:00pm CT; withUrgent After Hours
OUR COMMITMENT
Patients & Caregivers. At Agios, people living genetically defined diseases are at the center of everything we do and every decision we make. We are guided by a deep-rooted commitment to creating treatment options that make a meaningful difference in patients’ lives and fundamentally change the way genetically defined diseases are treated.DATA SHARING
Data Sharing with Researchers: Agios is committed to sharing clinical trial data with scientific researchers in the interest of advancing public health. Agios will consider external requests from qualified researchers for data derived from completed Agios-sponsored interventional clinical trials conducted in patients for products andTERMS OF USE
Terms and Conditions Governing the Use of the Agios Website Introduction. Welcome to the Agios website (“website”). Agios created and maintains this website to provide information to and communicate better with physicians, patients, investors and others who may be interested in learning more about Agios and the products andservices it offers.
OUR VALUES | AGIOS | THE OTHER SIDE OF POSSIBLE Our Values. At Agios, our culture and values – which form the foundation of our company and differentiate us – are embodied in the Greek word Arete, the ancient ideal of excellence and fulfillment of one’s potential. Arete has several meanings, and each is applicable to our company. It is often used to describe virtue, to characterizePRESS RELEASES
2021 Press Releases. May 12, 2021. Summary Toggle. Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress. Apr 29, 2021.INVESTOR OVERVIEW
The Investor Relations website contains information about Agios Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.BRUCE CAR, PH.D.
Bruce Car, Ph.D. Dr. Car spent 25 years at Bristol-Myers Squibb (BMS) and its legacy companies, working across all therapeutic areas and drug modalities, and serving most recently as the interim head, BMS drug discovery. For more than two decades, he held roles of increasing responsibility in drug discovery, covering all therapeutic areas, drug AGIOS ANNOUNCES DATA FROM ONGOING PHASE 1/2 TRIAL OF AG Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives ofToggle navigation
* __linkedin
* __Twitter
* Patients & Caregivers* Our Commitment
* Investigational Medicines* Clinical Trials
* Pyruvate Kinase Deficiency* Patient Resources
* Medical Professionals* Careers
* Our Values
* Inside Agios
* Find a Job
* Benefits
* Commitment to Our Community* Investors
* About Us
* About Us
* Our Values
* Valuing Differences* Leadership
* Board of Directors * Scientific Advisors* Founders
* Our History
* Corporate Responsibility & Sustainability* Research
* Our Research Platform* Publications
* Pipeline
* News & Events
* Press Releases
* Events & Webcasts
* Contact Us
WE ARE AT AN INFLECTION POINT. WE ARE INCREDIBLY PROUD OF THE PROGRESS WE HAVE MADE AS A COMPANY, THE DIFFERENCE WE ARE MAKING IN PATIENTS’ LIVES AND THE PEOPLE WHO GOT US HERE. OUR SUCCESSES HAVE RESULTED IN A WEALTH OF PROMISE AND OPPORTUNITY. MOVING FORWARD, WE WILL REIMAGINE OUR FUTURE TO CREATE EVEN MORE VALUE FOR PATIENTS, EMPLOYEES ANDINVESTORS.
Learn More
WHERE SCIENCE
MEETS HEART
__
Our Drive to ImprovePatients’ Lives
05/12/2021
Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia ...Latest News__
OUR STATEMENT ON
COVID-19
OUR STATEMENT ON
COVID-19
Learn More__
OUR COMMITMENT
TO CORPORATE RESPONSIBILITY View our 2021 environmental, social and governance (ESG) report.OUR COMMITMENT
TO CORPORATE RESPONSIBILITY View our 2021 environmental, social and governance (ESG) report.Read More__
SPIRIT OF AGIOS
Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, values and competencies. We have built on our core differentiators to make a positive difference for patients through truly differentiated therapies. This foundation will remain constant at Agios and accelerate our impact movingforward.
* Strengths and Competencies * Culture and Values career opportunitiesAgios
has a dynamic culture that fosters our employees’ unwavering commitment to patients, science and each other. PATIENTS & CAREGIVERS* Our Commitment
* Investigational Medicines* Clinical Trials
* Pyruvate Kinase Deficiency* Patient Resources
MEDICAL PROFESSIONALS * Medical ProfessionalsCAREERS
* Our Values
* Inside Agios
* Find a Job
* Benefits
* Commitment to Our CommunityINVESTORS
* Overview
* Press Releases
* Events & Presentations* Stock Information
* Financials
* Resources
* Contact Us
ABOUT US
* About Us
* Our Values
* Leadership
* Board of Directors * Scientific Advisors* Founders
* Our History
* Corporate Responsibility & SustainabilityRESEARCH
* Our Research Platform* Publications
PIPELINE
* Pipeline
NEWS & EVENTS
* Press Releases
* Events & Webcasts
CONTACT US
* Contact Us
* © 2021 Agios, Inc. All rights reserved.* Privacy Notice
* Cookies Preferences* Copyright Info
* Terms of Use
* Compliance
* Sitemap
* Contact Us
* Do Not Sell My Personal Information COOKIES PREFERENCES CENTER When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. Privacy Notice ." class="privacy-notice-link" target="_blank" aria-label="Privacy Notice, Opens in a new window">Privacy NoticeAllow All
MANAGE CONSENT PREFERENCES STRICTLY NECESSARY COOKIESAlways Active
Strictly Necessary Cookies These cookies are essential to provide you with services available through our sites and to enable you to use some of their features. Without these cookies, the services that you request may not be possible to provide. We only use these cookies to provide you withthose services.
Cookies Details
PERFORMANCE COOKIES
Always Active
Performance Cookies
These cookies are used to collect information about traffic to our sites and how users use our sites. The information gathered may include the number of visitors to our sites, the websites that referred them to our sites, the pages they visited on our sites, what time of day they visited our sites, whether they have visited our sites before, and other similar information. We use this information to help operate our sites more efficiently, to gather demographic information and to monitor the level of activity on our sites.Cookies Details
TARGETING COOKIES
Always Active
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.Cookies Details
Confirm My Choices
Back Button
Back
PERFORMANCE COOKIES
Vendor Search Search Icon Filter IconClear Filters
Information storage and accessApply Consent Leg.InterestAll Consent Allowed
Select All Vendors
Select All Vendors
Select All Hosts
*
33ACROSS
HOST DESCRIPTION
VIEW COOKIES
REPLACE-WITH-DYANMIC-HOST-ID*
Name
cookie name
Confirm My Choices
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0